Skip Links
10 of 45 items
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company.
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, held its Annual General Meeting earlier today at which all resolutions were duly passed.
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company, as announced on 3 November 2009.
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, confirms that its Annual Report and Accounts for the year ended 30 June 2009 is today being posted to shareholders.
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today announces that it is in discussions which may or may not lead to an offer being made for the Company. The Company further confirms that it is seeking a sale or merger of the Company in order that the value of its pipeline can be maximised. Piper Jaffray Ltd. has been appointed to advise the Company in connection with this process.
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, is pleased to announce its preliminary results for the year ended 30 June 2009
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on neurodevelopmental disorders, will announce its preliminary results for the year ended 30 June 2009 on Wednesday 30 September 2009.
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on neurodevelopmental disorders, today announces an interim update to its shareholders on significant progress during the past three months.
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on developmental disorders, notes the existence of market rumour and the recent movement in its share price. The Company confirms that it received an indicative indication of interest with respect to a possible M&A transaction from a third party and that this interest is not being pursued. It further confirms that it is not currently in M&A discussions and is not aware of any specific reason for the share price movement.
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on developmental disorders, is pleased to announce its half-year results for the six months ended 31 December 2008.
10 of 45 items